Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.75 |
| ▸ | RAB9A | P51151 | 9/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | SCN4A | P35499 | 2/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4307773 | 0.99 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL2709859 | 0.95 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| Hydrochloric Acid SCHEMBL334836 | 0.93 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL24329835 | 0.86 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| Fumaric Acid SCHEMBL3468728 | 0.85 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| Fumaric Acid SCHEMBL3468731 | 0.85 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL4056087 | 0.83 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL10219273 | 0.81 | SCN4A (0.62) | NPC1RAB9ASMN1; SMN2MAPTSCN4A | |
| SCHEMBL3216411 | 0.81 | RAB9A (0.60) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL3552178 | 0.80 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-11160803-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2021-11-02 | — | — | US | disclosed |
| US-10449192-B2 | Phthalazinone derivatives | KUDO PHARMACEUTICALS LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-9566276-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-02-14 | — | — | US | disclosed |
| US-20160000781-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-9169235-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2015-10-27 | — | — | US | disclosed |
| EP-2001485-B1 | DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140378442-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED | 2008-08-21 | — | — | US | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007126935-A2 | DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007090617-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2007-08-16 | — | — | WO | disclosed |
| US-20060149059-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1633724-A1 | PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-20050059663-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-03-17 | — | — | US | disclosed |
| US-6821967-B2 | AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-11-23 | — | — | US | disclosed |
| WO-2004080976-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | MTTP, CETP, CPT1A | NPC1 10/4885RAB9A 3175/4885SMN1; SMN2 4276/4885 |
| US-20140378442-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | NPC1 1933/4885RAB9A 3332/4885SMN1; SMN2 3730/4885 |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | NPC1 1989/4885RAB9A 3570/4885SMN1; SMN2 3650/4885 |
| US-20050059663-A1 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | NPC1 1933/4885RAB9A 3332/4885SMN1; SMN2 3730/4885 |
| US-10449192-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | NPC1 1933/4885RAB9A 3332/4885SMN1; SMN2 3730/4885 |
| US-11160803-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | NPC1 1933/4885RAB9A 3332/4885SMN1; SMN2 3730/4885 |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | PARP1, PARP11, PARP2 | NPC1 4492/4885RAB9A 4538/4885SMN1; SMN2 553/4885 |
| US-20060149059-A1 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | NPC1 1989/4885RAB9A 3570/4885SMN1; SMN2 3650/4885 |
| US-20160000781-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | NPC1 1933/4885RAB9A 3332/4885SMN1; SMN2 3730/4885 |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | NPC1 1989/4885RAB9A 3570/4885SMN1; SMN2 3650/4885 |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | NPC1 1933/4885RAB9A 3332/4885SMN1; SMN2 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.